[Improved results in children with acute lymphoblastic leukemia treated with the ALL-BFM 90 protocol in the Czech Republic]
| Autor: | J, Starý, P, Gajdos, B, Blazek, H, Ptoszková, V, Mihál, D, Pospísilová, H, Hrstková, D, Dembická, L, Kopecná, Z, Slavík, J, Hak, D, Procházková, F, Zahálka, Z, Cerná, Y, Jabali, P, Timr, V, Vávra, J, Mydlil, O, Hrusák, J, Trka |
|---|---|
| Jazyk: | čeština |
| Rok vydání: | 2003 |
| Předmět: |
Male
Adolescent Mercaptopurine Daunorubicin Cytarabine Infant Precursor Cell Lymphoblastic Leukemia-Lymphoma Prognosis Disease-Free Survival Methotrexate Recurrence Vincristine Child Preschool Antineoplastic Combined Chemotherapy Protocols Asparaginase Humans Prednisone Female Child Cyclophosphamide Follow-Up Studies |
| Zdroj: | Casopis lekaru ceskych. 142(7) |
| ISSN: | 0008-7335 |
| Popis: | Prognosis of children with acute lymphoblastic leukaemia (ALL)--the most common cancer in childhood, has improved remarkably over the last 40 years. The authors report the treatment outcome in children with ALL cured according to ALL-BFM 90 Study protocol in the Czech Republic during the first half of nineties.Children aged 0-18 years were included into the study in 10 centers between 1990 to 1996. Patients were classified into standard-risk (SR), medium-risk (MR) and high-risk (HR) group according to initial leukaemic burden, early treatment response, and genotype of leukaemia. Duration of the chemotherapy was two years. Treatment results were evaluated in 352 children. With a median follow-up of 7.3 years, event-free-survival (EFS) was 71.3% and overall survival 76.4%. EFS was 80.3%, 74% and 28.2% in SR, MR and HR group, respectively. Relapse was diagnosed in 17.8% of the patients.The treatment outcome of children with ALL improved significantly (p = 0.0045) compared to the previous study ALL-BFM 83 (EFS 62%). These results are comparable to those achieved by leading leukaemia study groups in the world. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|